NCT01579968

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 86 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) when undergoing surgery under normal clinical practice conditions.

Conditions

• Congenital Bleeding Disorder
• Haemophilia A With Inhibitors
• Haemophilia B With Inhibitors

Interventions

Type	Name	Description
DRUG	eptacog alfa (activated)	Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice

Timeline

• Start date: 1999-03-10
• Primary completion: 2010-03-09
• Completion: 2010-03-09
• First posted: 2012-04-18
• Last updated: 2017-02-24

Locations

1 site across 1 country: Japan